ABSTRACT. Human cystinotic fibroblasts were completely depleted of their accumulated intracellular free cystine within a 2-h time interval when exposed to culture medium containing between 1 and 5 mM mercaptoethylgluconamide. This cystine-depleting action of mercaptoethylgluconamide was observed with three different human cystinotic fibroblast cell lines and with all three cell lines, 2 mM mercaptoethylgluconamide was as effective as 1 mM cysteamine in depleting cells of their intracellular free cystine. Cell viability was excellent for cystinotic fibroblasts exposed to 2 mM mercaptoethylgluconamide for up to 6 days in duration. Mercaptoethylgluconamide (2 mM) was sufficiently stable under cell culture conditions such that a single addition of mercaptoethylgluconamide maintained cystine depletion in human cystinotic fibroblasts for at least a 4-day period. In contrast to cysteamine, 2 mM mercaptoethylgluconamide was not capable of depleting the cystine content of isolated cystinotic lysosomes, implying that cellular integrity is necessary to achieve cystine 
strated that the aminothiol, cysteamine, could effectively deplete cystinotic cells of their high intralysosomal accumulation of cystine both in vitro and in vivo. A subsequent multicenter trial has shown that cysteamine treatment preserves renal glomerular function and improves linear growth (9) . Despite the clinical success of cysteamine it has a significant disadvantage in that it has an unpalatable taste, hence other cystine-depleting drugs are required. This report describes the ability of the carbohydrate derivative, MEG, to deplete human cystinotic fibroblasts of their accumulated cystine in a very effective manner.
MATERIALS AND METHODS
Diploid human fibroblasts were cultured in Coon's modified Ham's F-12 medium supplemented with 10% (v/v) fetal bovine serum and incubated at 37°C in a humidified incubator flushed with an air/CO, (19:l) mixture. Cystine-free medium was the same medium with cystine deleted and supplemented with 10% dialyzed fetal bovine serum. Experiments were performed with fibroblasts grown to a confluent state on 60-mm culture dishes. WG 1522 is a fibroblast line derived from skin biopsy of a 1 1 -mo-old cystinotic child, GM0090A is a human cystinotic fetal lung fibroblast cell line purchased from the Human Genetic Mutant Cell Repository (Camden, NJ), and DFL is a human fetal lung fibroblast line grown from a cystinotic fetus.
Cells were harvested by trypsin treatment and cell number determined by a model ZF Coulter counter (Coulter Instruments, Inc., Hialeah, FL). Cell viabilities were determined by trypan blue exclusion (1 1) and by a 4-h cell attachment assay. In the cell attachment assay, trypsinized cells were allowed to attach to a 60-mm culture dish for 4 h at 37°C in culture medium containing 10% fetal bovine serum. Then each dish was washed three times with PBS, retrypsinized, and the number of cells recovered at this point divided by the number of cells at the initial trypsinization was taken as a more stringent measure of cell viability (1 2).
Total free cystine was measured by a cystine binding protein assay (1 3). In other experiments, confluent fibroblast monolayers were cultured for 18-24 h in complete medium containing 35S-cystine (1.0 x 10"pm/ml) to radiolabel the lysosomal cystine pool. Cell monolayers were then washed three times with PBS, and incubated in cystine-free culture medium containing either 1 mM cysteamine, 2 mM MEG, or, in the case of the control, no further addition. At intervals, the cells were harvested by trypsin treatment and immediately broken by sonic disruption in a 5 mM N-ethylmaleimide/lOO mM sodium phosphate buffer, pH 7.4. Cell proteins were precipitated by centrifugation after addition of sulfosalicylic acid to 3% (v/v), and the supernatant, along with internal standards of cystine and cysteine-NEM, were analyzed by one-dimensional high voltage electrophoresis in 6% formic acid at 3500 V for 25 min. The paper was dried, the standards visualized by the use of a ninhydrin spray, and radioactivity comigrating with the cystine standard was cut out and counted in 10 ml of Bio-Safe I1 scintillation fluid (Research Products International Corp., Mt. Prospect, IL) (8) .
Purified fibroblast lysosomes were prepared as previously described by centrifugation through Percoll density gradients (14) . These lysosomes were pre-loaded with 35S-cystine by incubating for 1 h at 37°C with 10 pCi of 35S-cystine dimethyl ester (2 Ci/ mmol) in 0.3 ml of 10 mM MOPS/Tris pH 7.6 buffer containing 0.25 M sucrose and 1 mM Na2EDTA (15) . Lysosomes were then diluted to 1.5 ml with ice-cold buffer, centrifuged for 8 min at 4°C in a model 5415 Eppendorf microcentrifuge (Brinkmann Instruments, Westbury, NY) , and the supernatant discarded. The lysosomal pellet was resuspended in 1.5 ml of ice-cold buffer and washed once more by centrifugation. The final lysosomal pellet was resuspended to 115 p1 with ice-cold 40 mM MOPS/ Tris pH 7.0 buffer containing 0.25 M sucrose. The "S-cystineloaded lysosomal suspension was divided in equal aliquots and then mixed with an equivalent volume of 40 mM MOPS/Tris pH 7.0 buffer containing either 2 mM cysteamine, 4 mM MEG or no further addition. The suspensions were incubated at 37°C for 45 min then diluted to 1.5 ml with ice-cold 20 mM MOPS/ Tris pH 7.0 buffer containing 0.275 M mannitol and 10 mM Nethylmaleimide and centrifuged for 10 min at 15, 600 x g in an Eppendorf microcentrifuge at 4°C. The supernatants were discarded and the lysosomal pellets were resuspended in 90 p1 of 12 mM N-ethylmaleimide in 10 mM sodium phosphate pH 7.5 buffer containing 0.1 % Triton. Proteins were precipitated in each tube by centrifugation after the addition of sulfosalicyclic acid to 4% (v/v) and 10 p1 aliquots of the supernatants were analyzed by one-dimensional high voltage electrophoresis as described above. The "S-cystine dimethyl ester was prepared from "Scystine as described previously (16) and purified by methanol elution of the radioactivity migrating with the cystine dimethyl ester standard after one-dimensional high voltage electrophoresis in 6% formic acid.
Cysteamine was purchased from Sigma Chemical Co. 
RESULTS
We have previously shown that when cystinotic fibroblasts are placed in culture medium containing I mM cysteamine, the cystine content of these fibroblasts is rapidly depleted, reaching within 30-60 min, a level approaching that found in normal fibroblasts (8) . We now report that 2 mM MEG depletes cystinotic fibroblasts of their intracellular free cystine to the same low level as achieved with I mM cysteamine. Time courses comparing the cystine depleting action of 1 mM cysteamine and 2 mM MEG are shown in Figure 1 . Nearly identical time collrses of cystine depletion by 2 mM MEG were obtained with three different cystinotic fibroblast cell lines. Time courses of cystine depletion were very similar whether intracellular cystine levels were quantified using a cystine binding protein assay or by measurement of free [35S]cystine as described in "Materials and Methods" (data not shown). In all cystinotic cell lines, the rate of cystine depletion by 2 mM MEG was somewhat slower than that by cysteamine, requiring approximately 2 h to reach complete depletion as compared to 30 min for I mM cysteamine. For reference, the structures of MEG and cysteamine are provided in Figure 2 .
A study of the dependence of cystine depletion on the concentration of mercaptoethylgluconamide indicates that MEG concentrations as low as 0.1 mM provide a substantial level of ' MEG is no longer routinely available from Vega but a method for its synthesis is provided in Reference 10. cystine depletion within 4 h (Fig. 3) . Increasing the concentration of mercaptoethylgluconamide results in a faster rate of cystine depletion although the same final level of depletion is reached with concentrations of MEG ranging from I to 5 mM. The rate of cystine depletion obtained with 5 mM MEG is approximately one-half the rate obtained with 1 mM cysteamine shown in Figure 1 .
Several experiments were performed to assess the effects of exposing cystinotic fibroblasts to 2 mM MEG for periods of time more than 4 h. Culture dishes of cystinotic fibroblasts were placed in medium containing 2 mM MEG on day 0, the cells were subsequently harvested at days 0, 1, 2, 3, and 4 of culture, and intracellular free cystine levels were measured. The results shown in Figure 4 indicate that MEG is able to maintain cystine * Percoll-purified lysosomes prepared from three confluent roller bottles of GM 0090A cystinotic fibroblasts were loaded with 3SS-cystine by incubation with 35S-cystine dimethyl ester as described in "Materials and Methods." The 35S-cystine-loaded lysosomes were washed free of unaccumulated "S-cystine dimethyl ester by centrifugation and then incubated at 37°C for 45 min with 40 mM MOPS/Tris pH 7.0 buffer containing either 1 mM cysteamine, 2 mM mercaptoethylgluconamide, or no further addition. At the end of this time interval, lysosomes were collected by centrifugation and the amount of free 35S-cystine remaining in each lysosomal pellet was determined by high voltage electrophoresis as described in "Materials and Methods." of cysteamine to react with lysosomal cystine by sulfhydryl/ disulfide exchange to form cysteine and the mixed disulfide of cysteamine and cysteine (8) . The mixed disulfide of cysteamine and cysteine is then transported out of the lysosome by lysosomal system c (15, 17) whereas cysteine may leave the lysosome by the transport systems for the small neutral amino acids, systems e and f (14) . Both reaction products then enter normal cellular metabolic pathways. Thus, cysteamine produces cystine depletion by converting cystine to products which are recognized by other functional lysosomal transport systems, allowing for net exodus of cystine. The mechanism responsible for the cystinedepleting action of MEG is not yet clear. When directly reacted with cystine, MEG can readily reduce cystine. Our experiments indicate, however, that MEG by itself is not capable of traversing the membranes of isolated lysosomes. This suggests that either an MEG metabolite, possibly formed in the cytosol, is responsible for the cystine-de'pleting action of MEG, or that cellular integrity is required for the delivery of MEG to the lysosomal compartment allowing reaction with intralysosomal cystine. A mixed disulfide of MEG and cysteine formed in the lysosomal compartment is not likely to be recognized by lysosomal system c because it would lack a positively charged side chain necessary for recognition by lysosomal system c. The mixed disulfide of MEG and cysteine, however, could possibly be recognized by the transport system for large, hydrophobic amino acids, lysosoma1 system h (18), or by a transport system not yet characterized. Regarding the possible metabolism of MEG, it is conceivable that an enzymatic hydrolysis of the amide bond in MEG could produce cysteamine in situ which then could traverse the lysosomal membrane and cause cystine depletion.
MEG represents a new class of agent capable of depleting cystinotic fibroblasts of their accumulated cystine. Good retention of cell viability is observed when cystinotic fibroblasts are exposed to 2 mM MEG for periods of at least 6 days in duration. Importantly, we have not noticed any substantial offensive odor associated with the MEG used in this study and others have recently noted that MEG is odorless (10) . Thus, in this regard MEG appears superior to cysteamine which has a conspicuous thiol odor and taste.
MEG also displays good solubility and, as a carbohydrate, could be joined to other carbohydrates by specific linkages to yield a polymer containing many MEG residues. This provides new opportunities for drug design. For example, such a polymer with the appropriate linkages, cleavable by enzymes present in lacrimal secretions could permit a sustained release of MEG for dissolving the corneal crystals arising in cystinosis (19) (20) (21) (22) . The potential beneficial applications of mercaptoethylgluconamide for complementing or supplanting the use of cysteamine in treating cystinosis or possibly other diseases warrants further clinical investigation.
